- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.
"I'm thrilled to join Dyne. I was drawn to the recent compelling clinical data for the DM1 and DMD programs and the potential to leverage the FORCE™ platform in other diseases. Having worked extensively in rare diseases, I appreciate the meaningful impact that novel therapeutics can have on a patient community," said Mr. Cox. "I'm looking forward to working with the team to further advance our clinical programs and our pipeline and to build additional capabilities as Dyne continues to create value for all its stakeholders."
"It's been a great privilege to lead Dyne since 2019. I want to thank the Board and all Dynamos for their support, and I'm proud of all that we have accomplished together," said Mr. Brumm. "This is the right time to hand the reins to John to work with the incredible Dyne team to prepare for the company's exciting next phase and continued pursuit of its mission of delivering life-transforming therapies for patients."
"I want to thank Josh for his leadership as Dyne transitioned from a research organization to a clinical-stage company. It's remarkable what he and the team have achieved in ...